Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.

MLA

Rosner, Samuel, et al. “Divergent Clinical and Immunologic Outcomes Based on STK11 Co-Mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 2, Jan. 2025, pp. 339–51. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-2983.

APA

Rosner, S., Connor, S., Sanber, K., Zahurak, M., Zhang, T., Gurumurthy, I., Zeng, Z., Presson, B., Singh, D., Rayes, R., Sivapalan, L., Pereira, G., Ji, Z., Thummalapalli, R., Reuss, J. E., Broderick, S. R., Jones, D. R., Deutsch, J. S., Cottrell, T. R., … Smith, K. N. (2025). Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 31(2), 339–351. https://doi.org/10.1158/1078-0432.CCR-24-2983

Chicago

Rosner, Samuel, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang, Isha Gurumurthy, Zhen Zeng, et al. 2025. “Divergent Clinical and Immunologic Outcomes Based on STK11 Co-Mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31 (2): 339–51. doi:10.1158/1078-0432.CCR-24-2983.